Galderma Laboratories (Clindagel) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Galderma Laboratories (Clindagel) General Information

Description

The asset is a worldwide rights of clindamycin phosphate gel. The clindamycin phosphate gel comes under the brand name Clindagel® is a prescription topical antibiotic for the treatment of acne. The gel is the only FDA-approved topical formulation of clindamycin phosphate with once daily dose.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Onset Dermatologics
Primary Office
  • Avenue Gratta-Paille 2
  • 1018 Lausanne
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Galderma Laboratories (Clindagel) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Galderma Laboratories (Clindagel)‘s full profile, request access.

Request a free trial